Click For Photo: https://i.dailymail.co.uk/i/newpix/2018/07/25/14/4E8E87A800000578-0-image-a-5_1532523669276.jpg
A 'critically low' number of clinical trials are being carried out into dementia treatments around the world, according to experts.
While there are more than 1,000 currently active clinical trials trying to beat cancer globally, there are just 142 looking at Alzheimer's disease, the main cause of dementia.
Phase - Times - Cancer - Trials - Stage
And only 29 of those have progressed past the first phase of testing – 40 times fewer than cancer trials at the same stage.
Dementia, a disabling loss of brain function, affects around 850,000 people in the UK and 40 million worldwide and is rising – a million Brits are expected to have it by 2025.
Scientists - Illness - Priority - Treatments
Scientists say researching how to slow down or treat the illness is now an 'urgent priority' because there have been no new treatments licensed since the 1990s.
Research by the University of Exeter has revealed scientists around the world are not doing enough to tackle dementia.
Dementia - Effects - Brain - Degeneration - Age
Dementia describes the effects of brain degeneration, usually because of age, which can cause memory loss, behaviour changes, speech problems and disability, eventually causing death.
At the Alzheimer's Association International Conference this week, researchers highlighted the shortfall in clinical research and explained the work being done.
Number - Trials
'The number of clinical trials is critically low'
Exeter's Professor Clive Ballard said: 'When we drilled down into the number of active clinical trials in dementia we revealed that the number that could make a meaningful difference to treating disease is now critically low.
Treatments - Years - Shortfall - Priority
'With no new licensed treatments in the last 20 years, addressing this shortfall is an urgent priority.
'Our research outlines the new approach needed to enable us to do...
Wake Up To Breaking News!